The ISPOR good practice modeling principles - A sensible approach: Be transparent, be reasonable

被引：27
作者：
Garrison, LP [1 ]
机构：
[1] F Hoffmann La Roche & Co Ltd, Div Pharmaceut, CH-4002 Basel, Switzerland
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 01期
关键词：
D O I：
10.1046/j.1524-4733.2003.00003.x
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：6 / 8
页数：3
相关论文
共 4 条
[1]   Time for a change in drug licensing requirements? [J].
Michael F. Drummond .
The European Journal of Health Economics, 2002, 3 (2) :137-138
[2]  
Gold MR, 1996, COST EFFECTIVENESS H
[3]  
PAULY M, 1996, C PAP POL ISS PHAR C
[4]   Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices-modeling studies [J].
Weinstein, MC ;
O'Brien, B ;
Hornberger, J ;
Jackson, J ;
Johannesson, M ;
McCabe, C ;
Luce, BR .
VALUE IN HEALTH, 2003, 6 (01) :9-17
1